Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

Expert opinion on biological therapy·2026

Same author

When cure exists but access does not.

Nature medicine·2026

Same author

Novel phosphatase-based regulatory loop for HbF expression.

Blood·2026

Same author

How I manage luspatercept in transfusion-dependent beta-thalassemia.

HemaSphere·2026

Same author

Spirituality and cancer: quality of life, anxiety/depression and symptom severity.

BMJ supportive & palliative care·2025

Same author

From Science to Solidarity: A Two-Decade Collaboration in Thalassemia.

American journal of hematology·2025

Search research articles

Related Experiment Video

Updated: Jun 10, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Hypercoagulability in hemoglobinopathies: Decoding the thrombotic threat.

Rayan Bou-Fakhredin^1,2, Maria Domenica Cappellini², Ali T Taher³

¹Department of Clinical Sciences and Community, University of Milan, Milan, Italy.

American Journal of Hematology

|October 14, 2024

Summary

This summary is machine-generated.

Beta-thalassemia and sickle cell disease cause a hypercoagulable state, increasing thrombosis risk. Understanding these mechanisms aids in developing better prevention and treatment strategies for patients.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

Related Experiment Videos

Last Updated: Jun 10, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

Area of Science:

Hematology
Vascular Biology
Genetics

Background:

Beta (β)-thalassemia and sickle cell disease (SCD) are associated with a hypercoagulable state.
This hypercoagulability significantly impacts organ complications and disease severity in these hemoglobinopathies.

Purpose of the Study:

To describe the pathogenesis of thrombosis in β-thalassemia and SCD.
To identify common mechanisms driving the procoagulant profile in hemoglobinopathies.
To review current prevention and management strategies for thrombosis in these patient populations.

Main Methods:

Literature review of thrombosis pathogenesis in β-thalassemia and SCD.
Analysis of contributing factors including red blood cells, erythroblasts, free heme, and inflammatory vasculopathy.
Synthesis of information on common procoagulant mechanisms and clinical management.

Main Results:

Red blood cells and erythroblasts are central to thrombosis in β-thalassemia and SCD.
Free heme, inflammatory vasculopathy, and splenectomy are additional contributors to thrombotic risk.
Common mechanisms underlie the procoagulant state in hemoglobinopathies leading to thrombotic events.

Conclusions:

Understanding the multifaceted drivers of hypercoagulability is crucial for improving preventive and therapeutic strategies.
Enhanced knowledge will facilitate the development of novel therapies for thrombosis in β-thalassemia and SCD.
Current prevention and management approaches require continued evaluation and potential enhancement.